Anthea Cheng

Ms. Anthea Cheng

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2023 in Transplant Infectious Disease
Verified
Journal Article
Open access
MDMartin Dutch
Martin Dutch
ACAnthea Cheng
Anthea Cheng
PKPhilip Kiely
Philip Kiely
CSClive Seed
Clive Seed
Background: Nucleic acid test window periods for HIV, HCV, and HBV facilitate estimation of the residual risk of unexpected disease transmission and assist clinicians in determining the timeframe in which a recently acquired infection is at risk of nondetection.Objectives: Firstly, to provide revised estimates of the NAT window periods based on a currently used triplex NAT assay. Secondly, to examine their validity in organ donation and transplantation practice.Method: Estimates were based on the Procleix Ultrio Elite Assay (Grifols Diagnostic Solutions Inc. California, USA). The manufacturer's X50 and X95 limits of detection (LOD) were utilised. Viral doubling times of 0.85, 0.45, and 2.56 days and conversion factors for IU per ml to copies per mL of 0.6, 3.4, and 5 were assumed for HIV, HCV, and HBV respectively. Window periods were derived from the X50 and X95 LODs, based on a range of potential inoculum volumes.Results: Calculated X50 window periods were 5.1 (4.5–5.8), 2.7 (2.4–2.9), and 16.6 (14.2–19.1) days for HIV, HCV, and HBV respectively.Calculated X50 window periods, based on whole body plasma volume, were 11.8 (10.3–13.3), 6.2 (5.6–6.8) and 36.7 (31.3–42.1) days respectively.Conclusion: X50 NAT window periods were significantly shorter for HBV and HCV and sit at the lower range of previously published estimates for HIV . Current modeling assumptions may not account for all unexpected transmission events and may no longer be suitable for application to organ donation and transplantation. image

19 September 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
ACAnthea Cheng
Anthea Cheng
ADAnindita Das
Anindita Das
KCKhin Chaw
Khin Chaw
PDPeta M. Dennington
Peta M. Dennington
CSClaire Styles
Claire Styles
IGIain B. Gosbell
Iain B. Gosbell
Transfusion-transmitted bacterial infection (TTBI) is the leading cause of transfusion-transmitted infections. Platelet components are more likely to be associated with bacterial contamination due to their storage requirements. Australian Red Cross Lifeblood introduced the bacterial contamination screening (BCS) of all platelet components in 2008. The process was recently updated with the use of BACT/ALERT® VIRTUO®, a large-volume delayed sampling (LVDS) protocol and extending platelet shelf-life to seven days. This article describes the results from the routine BCS of platelet components in Australia. Use of VIRTUO has resulted in lower false-positive rates, reducing wastage and improving platelet inventory. Our findings show that the combination of LVDS and VIRTUO improves the safety of platelet transfusions through earlier time to detection, especially for pathogenic bacterial species. Pathogenic bacteria grew within 24 h of incubation with a clear delineation between pathogenic and non-pathogenic species. The data show this protocol is very safe, with no TTBI cases during this time. There were no TTBI reports in recipients of platelet components that subsequently had a positive culture with Cutibacterium species, probably due to the low pathogenic potential of these organisms and slow replication in aerobic platelet bags. We conclude there is no advantage in incubating culture bottles beyond five days.

14 August 2024 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
ACAnthea Cheng
Anthea Cheng
ADAnindita Das
Anindita Das
CSClaire Styles
Claire Styles
ZNZin Naing
Zin Naing
WRWiliam Rawlinson
Wiliam Rawlinson
IGIain B. Gosbell
Iain B. Gosbell
Using sequential immunoassays for the screening of blood donors is well described for viral serology testing but not for the screening of syphilis. In this study, we report the evaluation results and 2-year sequential testing data using two highly sensitive automated serology assays, the Alinity s Syphilis chemiluminescent immunoassay for screening, with all repeatedly reactive samples then tested on the Elecsys Syphilis electrochemiluminescence immunoassay. We screened 1,767,782 blood donor samples between 7 July 2021 and 6 July 2023 and found the Alinity false-positive rate to be low at 0.08% (1,456/1,767,782). The common false-positive rate between the two assays was also low (3.83%, 58/1,514). Concordantly reactive samples were further tested using a Treponema pallidum particle agglutination test, a rapid plasma reagin test, and a fluorescent treponemal antibody absorption test. There were 262/1,376 concordantly reactive Alinity and Elecsys blood donor samples with reactivity on one or more of the confirmatory tests. A total of 26/1,376 donors had a current syphilis infection, 152/1,376 reported a past history of syphilis and had been treated, and 84/1,376 did not report a past history of syphilis. We suggest that future studies could explore the use of sequential immunoassays to aid in the serodiagnosis for syphilis. IMPORTANCE: The serodiagnosis for syphilis usually follows two methodologies—a “traditional” algorithm using a non-treponemal test followed by confirmation using a treponemal test, or a “reverse” algorithm using a treponemal test followed by a non-treponemal test. There are limited reports in the literature of using a modified reverse algorithm (treponemal test followed by a second treponemal test), and to the best of knowledge, there are currently no published articles using two highly sensitive automated immunoassays to aid the serodiagnosis of syphilis. In addition, the Treponema pallidum particle agglutination (TPPA) assay is commonly used as a confirmatory test for the diagnosis of syphilis. With the withdrawal of the TPPA assay from Australia and presumably from the global market also, alternative testing algorithms are now required. This study provides proof of concept for using sequential immunoassays in the diagnosis of syphilis.

8 June 2025 in Vox Sanguinis
Verified
Journal Article
Open access
MGMichel‐Andrés García‐Otálora
Michel‐Andrés García‐Otálora
CMCarl McDonald
Carl McDonald
JBJennifer Bearne
Jennifer Bearne
BBBethany Brown
Bethany Brown
ACAnthea Cheng
Anthea Cheng
FBFor The Isbt Transfusion‐Transmitted Infectious Diseases Working Party Subgroup On Bacteria
For The Isbt Transfusion‐Transmitted Infectious Diseases Working Party Subgroup On Bacteria
Background and Objectives: High‐income countries have successfully enhanced platelet component (PC) safety with the implementation of mitigation strategies including donor screening, skin disinfection, first aliquot diversion and PC bacterial screening or treatment with pathogen reduction technologies (PRT). This review discusses the experiences of several institutions with the adoption of bacterial screening methods and/or PRT and highlights residual safety risks.Materials and Methods: Data from the American Red Cross (ARC), Australian Red Cross Lifeblood (Lifeblood), Canadian Blood Services (CBS), the Établissement Français du Sang (EFS) and National Health Service Blood and Transplant (NHSBT) were presented at the International Society of Blood Transfusion (ISBT) Congress, Transfusion‐Transmitted Infectious Diseases meeting (Barcelona, June 2024) and were summarised in this report.Results: PC screening with the automated BACT/ALERT culture system began in 2004 in the ARC and CBS, while the system was adopted in 2008 and 2011 by Lifeblood and NHSBT, respectively. Implementation of PC treatment with the PRT INTERCEPT started in 2016, 2022, and 2006 in the ARC, CBS, and EFS, correspondingly.Conclusions: PC screening and PC treatment with PRT have significantly increased product safety. However, there are still residual safety risks posed by challenging organisms such as sporulated Bacillus spp. and toxin‐producing Staphylococcus aureus.

14 November 2024 in Vox Sanguinis
Verified
Journal Article
Closed access
RLRyanne Lieshout‐Krikke
Ryanne Lieshout‐Krikke
VHVeronica Cecilia Hoad
Veronica Cecilia Hoad
SCSze Sze Chua
Sze Sze Chua
GKGrace Kam
Grace Kam
MSMasahiro Satake
Masahiro Satake
NDNancy Dunbar
Nancy Dunbar